• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs.野生型和V82F/I84V突变体的HIV-1蛋白酶分子动力学:对耐药性的可能贡献及潜在的药物新靶点
Protein Sci. 2004 Apr;13(4):1108-23. doi: 10.1110/ps.03468904.
2
Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design.针对HIV-1蛋白酶V82F/I84V耐药突变体的一系列潜在活性位点抑制剂的优化与计算评估:基于结构的药物设计中松弛复合物方法的应用
Chem Biol Drug Des. 2006 May;67(5):336-45. doi: 10.1111/j.1747-0285.2006.00382.x.
3
Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.野生型和双突变型HIV-1蛋白酶与安普那韦及两种安普那韦相关抑制剂复合的分子动力学和自由能研究:结合及耐药机制
J Med Chem. 2007 Mar 22;50(6):1177-88. doi: 10.1021/jm0609162. Epub 2007 Feb 15.
4
Restrained molecular dynamics simulations of HIV-1 protease: the first step in validating a new target for drug design.HIV-1蛋白酶的受限分子动力学模拟:药物设计新靶点验证的第一步。
Biopolymers. 2006 Jun 15;82(3):272-84. doi: 10.1002/bip.20497.
5
Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant.HIV-1蛋白酶抑制抗性的热力学基础:V82F/I84V活性位点抗性突变体的量热分析
Biochemistry. 2000 Oct 3;39(39):11876-83. doi: 10.1021/bi001013s.
6
A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.一种针对HIV-1蛋白酶耐药性突变的结构和热力学逃逸机制。
Proteins. 2004 May 15;55(3):594-602. doi: 10.1002/prot.20069.
7
A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions.一项比较野生型与多重耐药性HIV蛋白酶的分子动力学研究:瓣片和天冬氨酸25腔尺寸的差异。
Proteins. 2007 Nov 15;69(3):551-65. doi: 10.1002/prot.21535.
8
A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.一组非活性位点突变在HIV-1蛋白酶耐药性发展中起主要作用。
Biochemistry. 2003 Jan 28;42(3):631-8. doi: 10.1021/bi027019u.
9
Protein promiscuity: drug resistance and native functions--HIV-1 case.蛋白质的多特异性:耐药性与天然功能——以HIV-1为例
J Biomol Struct Dyn. 2005 Jun;22(6):615-24. doi: 10.1080/07391102.2005.10531228.
10
Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities.对抗HIV-1蛋白酶耐药性:与XV638和SD146(具有广泛特异性的环状脲酰胺)复合的突变蛋白酶的结构分析
Biochemistry. 1998 Oct 27;37(43):15042-9. doi: 10.1021/bi980386e.

引用本文的文献

1
Subtype-Specific HIV-1 Protease and the Role of Hinge and Flap Dynamics in Drug Resistance: A Subtype C Narrative.特定亚型的HIV-1蛋白酶以及铰链区和瓣区动力学在耐药性中的作用:C亚型的阐述
Viruses. 2025 Jul 26;17(8):1044. doi: 10.3390/v17081044.
2
Mechanism of drug resistance in HIV-1 protease subtype C in the presence of Atazanavir.在阿扎那韦存在的情况下,HIV-1 C型蛋白酶的耐药机制
Curr Res Struct Biol. 2024 Feb 20;7:100132. doi: 10.1016/j.crstbi.2024.100132. eCollection 2024.
3
FMO-guided design of darunavir analogs as HIV-1 protease inhibitors.基于 FMO 的达芦那韦类似物设计作为 HIV-1 蛋白酶抑制剂。
Sci Rep. 2024 Feb 13;14(1):3639. doi: 10.1038/s41598-024-53940-1.
4
Substitution Models of Protein Evolution with Selection on Enzymatic Activity.蛋白质进化的替代模型与酶活性选择。
Mol Biol Evol. 2024 Feb 1;41(2). doi: 10.1093/molbev/msae026.
5
Web Service for HIV Drug Resistance Prediction Based on Analysis of Amino Acid Substitutions in Main Drug Targets.基于主要药物靶点氨基酸替换分析的 HIV 耐药性预测的 Web 服务。
Viruses. 2023 Nov 11;15(11):2245. doi: 10.3390/v15112245.
6
Dynamozones are the most obvious sign of the evolution of conformational dynamics in HIV-1 protease.动力区是 HIV-1 蛋白酶构象动力学进化的最明显标志。
Sci Rep. 2023 Aug 30;13(1):14179. doi: 10.1038/s41598-023-40818-x.
7
HIV Protease Hinge Region Insertions at Codon 38 Affect Enzyme Kinetics, Conformational Stability and Dynamics.HIV 蛋白酶铰链区 38 位密码子的插入影响酶动力学、构象稳定性和动力学。
Protein J. 2023 Oct;42(5):490-501. doi: 10.1007/s10930-023-10132-6. Epub 2023 Jul 8.
8
Evolving Mutational Buildup in HIV-1 Protease Shifts Conformational Dynamics to Gain Drug Resistance.HIV-1 蛋白酶中的突变积累导致构象动力学改变从而获得耐药性。
J Chem Inf Model. 2023 Jun 26;63(12):3892-3902. doi: 10.1021/acs.jcim.3c00535. Epub 2023 Jun 7.
9
Implications of Fragment-Based Drug Discovery in Tuberculosis and HIV.基于片段的药物发现对结核病和艾滋病的影响。
Pharmaceuticals (Basel). 2022 Nov 15;15(11):1415. doi: 10.3390/ph15111415.
10
The structural, dynamic, and thermodynamic basis of darunavir resistance of a heavily mutated HIV-1 protease using molecular dynamics simulation.利用分子动力学模拟研究高度变异的HIV-1蛋白酶对达芦那韦耐药性的结构、动力学和热力学基础。
Front Mol Biosci. 2022 Aug 15;9:927373. doi: 10.3389/fmolb.2022.927373. eCollection 2022.

本文引用的文献

1
A solution NMR study of the binding kinetics and the internal dynamics of an HIV-1 protease-substrate complex.一项关于HIV-1蛋白酶-底物复合物结合动力学和内部动力学的溶液核磁共振研究。
Protein Sci. 2003 Jul;12(7):1376-85. doi: 10.1110/ps.0300703.
2
Cooperative fluctuations of unliganded and substrate-bound HIV-1 protease: a structure-based analysis on a variety of conformations from crystallography and molecular dynamics simulations.未结合配体和结合底物的HIV-1蛋白酶的协同波动:基于晶体学和分子动力学模拟的多种构象的结构分析
Proteins. 2003 May 15;51(3):409-22. doi: 10.1002/prot.10350.
3
The relaxed complex method: Accommodating receptor flexibility for drug design with an improved scoring scheme.松弛复合物方法:通过改进的评分方案在药物设计中考虑受体灵活性
Biopolymers. 2003 Jan;68(1):47-62. doi: 10.1002/bip.10218.
4
Human immunodeficiency virus reverse transcriptase and protease sequence database.人类免疫缺陷病毒逆转录酶和蛋白酶序列数据库。
Nucleic Acids Res. 2003 Jan 1;31(1):298-303. doi: 10.1093/nar/gkg100.
5
Drug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations.HIV-1蛋白酶中的耐药性:补偿性突变的灵活性辅助机制。
Protein Sci. 2002 Oct;11(10):2393-402. doi: 10.1110/ps.0206702.
6
Antiretroviral-drug resistance among patients recently infected with HIV.近期感染艾滋病毒患者中的抗逆转录病毒药物耐药性。
N Engl J Med. 2002 Aug 8;347(6):385-94. doi: 10.1056/NEJMoa013552.
7
Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.克服HIV-1化疗中的耐药性:安普那韦和TMC-126与HIV-1蛋白酶野生型及耐药突变体的结合热力学
Protein Sci. 2002 Aug;11(8):1908-16. doi: 10.1110/ps.0206402.
8
Role of conformational fluctuations in the enzymatic reaction of HIV-1 protease.构象波动在HIV-1蛋白酶酶促反应中的作用
J Mol Biol. 2002 May 31;319(2):567-83. doi: 10.1016/S0022-2836(02)00301-7.
9
Combining mutations in HIV-1 protease to understand mechanisms of resistance.合并HIV-1蛋白酶中的突变以了解耐药机制。
Proteins. 2002 Jul 1;48(1):107-16. doi: 10.1002/prot.10140.
10
Computational drug design accommodating receptor flexibility: the relaxed complex scheme.考虑受体灵活性的计算药物设计:松弛复合物方案。
J Am Chem Soc. 2002 May 22;124(20):5632-3. doi: 10.1021/ja0260162.

野生型和V82F/I84V突变体的HIV-1蛋白酶分子动力学:对耐药性的可能贡献及潜在的药物新靶点

HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs.

作者信息

Perryman Alexander L, Lin Jung-Hsin, McCammon J Andrew

机构信息

University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0365, USA.

出版信息

Protein Sci. 2004 Apr;13(4):1108-23. doi: 10.1110/ps.03468904.

DOI:10.1110/ps.03468904
PMID:15044738
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2280056/
Abstract

The protease from type 1 human immunodeficiency virus (HIV-1) is a critical drug target against which many therapeutically useful inhibitors have been developed; however, the set of viral strains in the population has been shifting to become more drug-resistant. Because indirect effects are contributing to drug resistance, an examination of the dynamic structures of a wild-type and a mutant could be insightful. Consequently, this study examined structural properties sampled during 22 nsec, all atom molecular dynamics (MD) simulations (in explicit water) of both a wild-type and the drug-resistant V82F/I84V mutant of HIV-1 protease. The V82F/I84V mutation significantly decreases the binding affinity of all HIV-1 protease inhibitors currently used clinically. Simulations have shown that the curling of the tips of the active site flaps immediately results in flap opening. In the 22-nsec MD simulations presented here, more frequent and more rapid curling of the mutant's active site flap tips was observed. The mutant protease's flaps also opened farther than the wild-type's flaps did and displayed more flexibility. This suggests that the effect of the mutations on the equilibrium between the semiopen and closed conformations could be one aspect of the mechanism of drug resistance for this mutant. In addition, correlated fluctuations in the active site and periphery were noted that point to a possible binding site for allosteric inhibitors.

摘要

1型人类免疫缺陷病毒(HIV-1)蛋白酶是一个关键的药物靶点,针对该靶点已开发出许多具有治疗作用的抑制剂;然而,病毒群体中的毒株类型一直在发生变化,变得更具耐药性。由于间接效应导致了耐药性,研究野生型和突变型的动态结构可能会有所启发。因此,本研究通过全原子分子动力学(MD)模拟(在明确的水环境中),对HIV-1蛋白酶的野生型和耐药性V82F/I84V突变体在22纳秒内的结构特性进行了研究。V82F/I84V突变显著降低了目前临床上使用的所有HIV-1蛋白酶抑制剂的结合亲和力。模拟表明,活性位点侧翼尖端的卷曲会立即导致侧翼打开。在此呈现的22纳秒MD模拟中,观察到突变体活性位点侧翼尖端的卷曲更频繁、更迅速。突变型蛋白酶的侧翼也比野生型的侧翼打开得更远,并且表现出更大的灵活性。这表明突变对半开放和封闭构象之间平衡的影响可能是该突变体耐药机制的一个方面。此外,还注意到活性位点和周边区域的相关波动,这指向了变构抑制剂的一个可能结合位点。